Phaseline

Targets › PDE6H

PDE6H (Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 4; Genitourinary, Cardiovascular, Neurology; next expected readout Dec 2026.

Inhibitory gamma subunit of the cone-specific cGMP phosphodiesterase (PDE6) complex which hydrolyzes 3',5'-cyclic GMP in the phototransduction cascade (By similarity). The PDE6 holoenzyme consists of two catalytic alpha subunits (PDE6C) and two inhibitory gamma subunits (PDE6H) (By similarity). (UniProt, Q13956)

Open in Phaseline: the race on PDE6H, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Vastra Gotaland RegionDipyridamole
Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor
SLC29A1, PDE5A, PDE4A, PDE3A, PDE6HPhase 4Takotsubo SyndromeDec 2028
Yunfeng XiaDipyridamole
Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor
SLC29A1, PDE5A, PDE4A, PDE3A, PDE6HPhase 2Restless Leg Syndrome Due to UraemiaDec 2026
Stanford UniversityDipyridamole
Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor
SLC29A1, PDE5A, PDE4A, PDE3A, PDE6HPhase 2HypophosphatemiaMay 2027

Conditions

Hypophosphatemia (1) Takotsubo Syndrome (1) Restless Leg Syndrome Due to Uraemia (1)

Modalities

small molecule (3)

Companies

Stanford University (1) Vastra Gotaland Region (1) Yunfeng Xia (1)

Related targets

SLC29A1 (3) PDE5A (3) PDE4A (3) PDE3A (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.